MD
Pediatrix Medical Group, Inc.Price & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $58.2M | the 2026 first quarter | — |
|
|
|||
| Adjusted EPS non-GAAP | $0.44 | the first quarter of 2026 | — |
| Same-unit revenue attributable to patient volume | -1.6% | the three months ended March 31, 2026 | — |
| Same-unit revenue from net reimbursement-related factors | 4.4% | the three months ended March 31, 2026 | — |
| Same-unit revenue growth | 2.8% | the three months ended March 31, 2026 | — |
| accounts receivable DSO | 42.5 | Q1 2026 call | — |
| capital deployed for share repurchases | $21M | Q1 2026 call | — |
| net non-same-unit activity | $6M | Q1 2026 call | — |
| NICU days change | -1% | Q1 2026 call | — |
| operating cash flow | -$130M | Q1 2026 call | — |
| practice-level S, W, and B expenses increase | $9M | Q1 2026 year over year call | — |
| pricing growth | 4% | Q1 2026 call | — |
| shares outstanding | 82M | Q1 2026 call | — |
| shares repurchased | 1M | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MD
this stock
Pediatrix Medical Group, Inc.
|
$2.20B | +25.1% | — | 13.0 | 4.6% |
|
HCA
HCA Healthcare, Inc.
|
$91.07B | -11.9% | +7.1% | 14.1 | 2.4% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$27.26B | -15.6% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$17.55B | +2.5% | -2.3% | 10.6 | 4.7% |
|
DVA
Davita Inc.
|
$15.08B | +106.8% | +6.5% | 21.9 | 7.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MD | +11.0% | +22.5% | +20.3% | +5.7% | +25.1% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +9.6% | +23.8% | +12.3% | +5.9% | +15.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.